In this study, we utilized a GEPR for erlotinib, an EGFR-TKI, which was generated in lung cancer cell lines, to test its predictive capacity in KRAS-wildtype mCRC patients treated with the anti-EGFR mAB cetuximab. Here, KRAS is linked to lung cancer.